CorMedix (CRMD) Retained Earnings (2010 - 2026)
CorMedix (CRMD) posted Retained Earnings of $581.8 million for Q4 2025, up 3.05% sequentially from $564.6 million in Q3 2025, and up 271.3% YoY from $156.7 million in Q4 2024.
CorMedix (CRMD) Retained Earnings (2010 - 2026) Analysis & Trends
CorMedix has reported Retained Earnings for 15 years, with the latest figure at $581.8 million in Q4 2025.
- Quarterly Retained Earnings rose 271.3% year-over-year to $581.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $581.8 million (up 271.3% YoY) and the FY2025 annual result came in at $581.8 million, up 271.3% from the prior year.
- Retained Earnings grew to $581.8 million in Q4 2025 per CRMD's latest filing, from $564.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at $581.8 million in Q4 2025 and troughed at -$339.6 million in Q4 2024.
- A 5-year average of $37.6 million and a median of $82583.0 in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 279834.28% in 2022, then jumped 389144.76% in 2024.
- Over 5 years, Retained Earnings stood at -$245.7 million in 2021, then slipped by 12.09% to -$275.4 million in 2022, then soared by 242.25% to $391.7 million in 2023, then sank by 186.71% to -$339.6 million in 2024, then surged by 271.3% to $581.8 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $581.8 million, $564.6 million, and $79435.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 572.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 572.74 Mn |
| Dec 31, 2025 | 581.80 Mn |
| Sep 30, 2025 | 564.56 Mn |
| Jun 30, 2025 | 79,435.00 |
| Mar 31, 2025 | -318.99 Mn |
| Dec 31, 2024 | -339.63 Mn |
| Sep 30, 2024 | 411.66 Mn |
| Jun 30, 2024 | 85,731.00 |
| Mar 31, 2024 | 394.04 Mn |
| Dec 31, 2023 | 391.69 Mn |
| Sep 30, 2023 | -306.95 Mn |
| Jun 30, 2023 | 346.12 Mn |
| Mar 31, 2023 | 101,232.00 |
| Dec 31, 2022 | -275.36 Mn |
| Sep 30, 2022 | -267.15 Mn |
| Jun 30, 2022 | -260.30 Mn |
| Mar 31, 2022 | 49,921.00 |
| Dec 31, 2021 | -245.66 Mn |
| Sep 30, 2021 | 95,502.00 |
| Jun 30, 2021 | -229.30 Mn |